What is Semax?

What is Semax?

Semax is a synthetic heptapeptide (7 amino acids) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues — Met-Glu-His-Phe — correspond to positions 4–7 of adrenocorticotropic hormone (ACTH). The final three residues, Pro-Gly-Pro, are a synthetic C-terminal extension not found in natural ACTH.

The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The structural logic behind Semax was deliberate: the ACTH 4-7 fragment retains neurological activity from the parent hormone but lacks the residues required for adrenal cortisol stimulation. Adding the Pro-Gly-Pro tail further improves enzymatic stability, extending its activity window by resisting rapid cleavage by proteases.

Semax has been used in Russian medicine since the late 1990s and has accumulated a substantial research literature on nootropic, neuroprotective, and anxiogenic/anxiolytic effects depending on model and context. Research interest outside Russia has grown significantly as BDNF-modulating compounds have become a central focus in neuroscience.

From ACTH to Semax: Why Fragment 4-7?

ACTH (39 amino acids) is a pituitary hormone best known for stimulating cortisol production from the adrenal cortex. But different segments of the ACTH sequence have different biological activities. Early research identified the middle fragment — particularly positions 4–10 — as the source of ACTH's behavioral and neurological effects, separate from its hormonal activity concentrated in the N-terminus (positions 1–3).

The ACTH 4–7 tetrapeptide (Met-Glu-His-Phe) retains the ability to influence neurotransmitter systems and neurotrophin expression without triggering adrenal cortisol release. This selectivity makes it an attractive starting point for CNS-targeted research compounds. However, the raw tetrapeptide degrades rapidly — peptidases cleave it within minutes in vivo.

The Pro-Gly-Pro extension at the C-terminus addresses this stability problem. Proline residues at the termini are resistant to exopeptidase cleavage, effectively capping the peptide and slowing its degradation. The result is a compound with the CNS-selective activity of ACTH 4–7 but meaningfully better pharmacokinetic durability — the defining engineering insight behind Semax.

How Semax Works

Semax's most consistently documented effect across rodent models is BDNF upregulation. BDNF (brain-derived neurotrophic factor) is a member of the neurotrophin family that promotes neuronal survival, facilitates long-term potentiation (LTP), and is essential for hippocampal neurogenesis. Multiple studies have shown Semax increases BDNF mRNA expression in the hippocampus and frontal cortex, regions central to memory and executive function.

Beyond BDNF, Semax has been shown to upregulate NGF (nerve growth factor) and NT-3 (neurotrophin-3) — related neurotrophins that support cholinergic neuron function and cerebellar development respectively. This broader neurotrophin upregulation profile distinguishes Semax from compounds that target a single neurotrophic pathway.

At the neurotransmitter level, Semax research has documented interactions with the serotonergic, dopaminergic, and cholinergic systems. It appears to enhance the activity of monoamine oxidase (MAO) inhibitor-sensitive pathways and has shown effects on dopamine turnover in striatal regions in rodent models. These neurotransmitter effects likely contribute to the cognitive and behavioral changes observed in animal research.

Semax also exerts anti-inflammatory and antioxidant effects in the CNS. Studies in ischemia models have demonstrated reductions in pro-inflammatory cytokines and oxidative stress markers following Semax administration. This neuroprotective activity may be relevant to the compound's observed effects in stroke models, where it has shown reduction of neurological deficit and improved recovery outcomes in rodents.

Intranasal Administration as a Research Model

One of the most distinctive aspects of Semax research is its focus on intranasal (IN) delivery. While many peptides require injection due to poor mucosal absorption, Semax's relatively small size (~813 Da) and structural properties make transmucosal absorption through the nasal epithelium viable.

The olfactory epithelium, which lines part of the nasal cavity, is of particular research interest because it offers a direct anatomical pathway to the CNS. The olfactory nerve and its projections to the olfactory bulb create a route by which nasally-applied compounds can bypass the blood-brain barrier via axonal transport and perineural diffusion. This so-called "olfactory pathway" has been documented for several neuropeptides and small molecules.

Research protocols for intranasal Semax typically involve a nasal spray atomizer device delivering precise volumes per nostril. Concentrations vary across studies, but the intranasal route generally requires a higher nominal dose than subcutaneous injection due to lower bioavailability. The practical research interest is in documenting how well CNS effects can be achieved via this non-invasive route compared to parenteral administration.

Semax vs Selank

Semax and Selank are often discussed together as the two flagship Russian-developed nootropic/neurological research peptides. Both support neurotrophic activity and modulate neurotransmitter systems, but they have distinctly different primary mechanisms and research applications.

Semax is primarily studied as a cognitive enhancer and neuroprotectant — it tends toward activating effects, upregulates BDNF significantly, and has been most explored in models of learning, memory, and stroke recovery. In some models it shows mild anxiogenic properties at higher doses, indicating stimulatory-type CNS activity.

Selank is primarily studied as an anxiolytic — derived from tuftsin (an immune tetrapeptide), it modulates the GABAergic system and increases BDNF at lower levels than Semax. Selank's research profile trends toward calming and anti-anxiety effects, with supporting memory data from reduced anxiety-driven interference. It does not carry the same activating profile as Semax.

Research Applications

Semax has been studied across a range of preclinical research areas. The most extensively documented applications are:

Reconstitution Protocol

Semax 10mg ships as a lyophilized (freeze-dried) powder. To reconstitute, add 2 mL of Bacteriostatic Water to the vial for a working concentration of 5 mg/mL. Inject the BAC water slowly down the vial wall and swirl gently — do not shake, as mechanical agitation can damage peptide structure. The solution should be clear and colorless.

Refrigerate at 2–8°C after reconstitution. Stable for 28–42 days. Semax is somewhat more temperature-sensitive in lyophilized form than longer, more stable peptides — store the unreconstituted vial at 2–8°C (not room temperature) to preserve potency. For intranasal research protocols, the reconstituted solution may be transferred to a sterile nasal spray atomizer; dilution with additional sterile saline or BAC water is sometimes used to achieve lower-concentration IN preparations.

Common Questions